z-logo
open-access-imgOpen Access
Anticuerpos postvacunales frente a SARS-CoV-2 en una cohorte de trabajadores de un hospital general
Author(s) -
Susana Sabater Vidal,
María Dolores Tirado-Balaguer,
Raquel Soria-Martín,
Alberto Arnedo-Pena,
Abel Gil-Galdón,
Ma Carmen Bellido-Cambrón,
Ma Rosario Moreno-Muñoz
Publication year - 2022
Publication title -
archivos de prevención de riesgos laborales
Language(s) - Spanish
Resource type - Journals
eISSN - 1578-2549
pISSN - 1138-9672
DOI - 10.12961/aprl.2022.25.04.03
Subject(s) - medicine , covid-19 , humanities , gynecology , art , disease , infectious disease (medical specialty)
The aim was to estimate the evolution of the levels of anti-SARS-CoV-2 antibodies, the associated factors, and the incidence of new infections during the follow-up period.  Method: Prospective cohort study of a representative sample of workers at the General University Hospital of Castellon 8 months after receiving the second dose of Pfizer-BioNTech vaccine against SARS-CoV-2, by determining IgG-S, IgG-NP, follow-up and response to a questionnaire. The results were compared with those at the start of the cohort in February 2021. Multivariate linear regression and Poisson regression were used.  Results: A total of 253 workers participated out of the 275 in the start of the cohort. All had detectable levels of IgG-S, median 691% AU/ml, decreasing by 93.3% compared with the first study. The decline of IgG-S increased with age and obesity; and decreased with a COVID-19 previous history, regular exercise, and in smokers. IgG-NP was positively associated with a history of COVID-19, taking vitamin D, and decreased from 4.4% to 1.2%. There were 4 new cases of COVID-19 in the cohort, with and incidence rate of 1.7%. One death occurred in a participant with immunosuppressive treatment, only one case was asymptomatic and no reinfections occurred.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here